Abstract
Neuroendocrine carcinoma of the upper gastrointestinal tract is an uncommon disease that manifests as a highly malignant tumor. We herein report a rare case of large cell neuroendocrine carcinoma of the esophagogastric junction treated with surgery and chemotherapy. A 65-year-old Japanese man was admitted to our hospital for treatment of a tumor of the esophagogastric junction detected by endoscopic examination. Biopsy specimens demonstrated large cell neuroendocrine carcinoma with highly frequent mitoses and positivity for synaptophysin, chromogranin A, and CD56. Computed tomography indicated at least three lymphadenopathies of the left and right cardiac nodes. We performed distal esophagectomy, total gastrectomy and pancreatosplenectomy, and subsequent S-1 adjuvant chemotherapy, but the patient died of liver metastasis 9 months after the surgery. Based on the outcome of the present case, this disease demands establishment of multimodal treatment that includes surgery and chemotherapy.
Similar content being viewed by others
References
Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53.
Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyons: IARC; 2010. p. 13–4.
Jiang SX, Mikami T, Umezawa A, Saegusa M, Kameya T, Okayasu I. Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity. Am J Surg Pathol. 2006;30:945–53.
Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.
Okamoto H, Fujishima F, Kasajima A, Miyata G, Onodera K, Kamei T, et al. A large cell neuroendocrine carcinoma of the esophagus (in japanese with english abstract). Jpn J Gastroenterol Surg. 2012;45:914–22.
Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
Ishida M, Sekine S, Fukagawa T, Ohashi M, Morita S, Taniguchi H, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37:949–59.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12.
Veits L, Lang-Schwarz C, Volkholz H, Falkeis C, Vieth M, Schulz H. Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction predominantly consisting of poorly differentiated neuroendocrine carcinoma. Endoscopy. 2013;45:16–7.
Japan Esophageal Society. Japanese classification of esophageal cancer, 10th edition: parts II and III. Esophagus. 2009; 6: 71–94.
Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168–72.
Matsui K, Jin XM, Kitagawa M, Miwa A. Clinicopathologic features of neuroendocrine carcinomas of the stomach: appraisal of small cell and large cell variants. Arch Pathol Lab Med. 1998;122:1010–7.
Namikawa T, Kobayashi M, Okabayashi T, Ozaki S, Nakamura S, Yamashita K, et al. Primary gastric small cell carcinoma: report of a case and review of the literature. Med Mol Morphol. 2005;38:256–61.
Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719–31.
Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000;128:408–16.
Ishida M, Morita S, Saka M, Fukagawa T, Taniguchi H, Katai H. Metachronous liver metastasis from early gastric cancer. J Gastrointest Surg. 2012;16:837–41.
Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, et al. Recurrences and related characteristics of gastric cancer. Br J Cancer. 1996;74:975–9.
Katai H, Maruyama K, Sasako M, Sano T, Okajima K, Kinoshita T, et al. Mode of recurrence after gastric cancer surgery. Dig Surg. 1994;11:99–103.
Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2006;24:70–6.
Badzio A, Kurowski K, Karnicka-Mlodkowska H, Jassem J. A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg. 2004;26:183–8.
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, National Comprehensive Cancer Network. Small cell lung cancer. J Natl Compr Cancer Netw. 2013;11:78–98.
Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24.
Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2010;5:867–73.
Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005;129:977–83.
Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, On behalf of the Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group and Lung Cancer Study Group of the Japan Clinical Oncology Group, et al. A phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206). Jpn J Clin Oncol. 2014;. doi:10.1093/jjco/hyt233.
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.
Okita NT, Kato K, Takahari D, Hirashima Y, Nakajima TE, Matsubara J, et al. Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma. Gastric Cancer. 2011;14:161–5.
Ethical Statement
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later revision. Informed consent or substitute for it was obtained from the present patient for being included in the study.
Conflict of interest
There are no financial or other relations that could lead to a conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fukuchi, M., Sakurai, S., Tsukagoshi, R. et al. A case of large cell neuroendocrine carcinoma of the esophagogastric junction. Esophagus 12, 295–299 (2015). https://doi.org/10.1007/s10388-014-0443-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10388-014-0443-7